GlassScriptPhysician profile
Tara Adhikari
NPI 1508068594
$8,606.18
in general payments reported to CMS, 2019-2025
34 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,430 · 2020: $1,334 · 2021: $1,196 · 2022: $1,197 · 2023: $510 · 2024: $557 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.02 |
| Education | $116.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,975.78 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $1,262.86 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Ucb, INC. | $956.29 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $826.06 | 2019-2025 | |
| Janssen Biotech, INC. | $584.42 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $458.77 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $429.39 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $370.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $264.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $179.72 | 2019-2025 | Benlysta |
| Hikma Pharmaceuticals USA | $132.72 | 2019-2022 | |
| Axsome Therapeutics, INC. | $119.97 | 2024 | Auvelity |
| Celgene Corporation | $115.82 | 2019 | |
| Boston Scientific Corporation | $110.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $96.04 | 2022-2025 | Saphnelo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $89.75 | 2019 | |
| Aurinia Pharma U.S., INC. | $86.98 | 2022-2025 | Lupkynis |
| Medexus Pharma, INC. | $60.96 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $59.99 | 2025 | Acthar |
| Merck Sharp & Dohme LLC | $52.04 | 2019 | |
| Cardinal Health INC | $42.85 | 2024 | |
| Mallinckrodt Enterprises LLC | $41.02 | 2019 | |
| Organon LLC | $40.41 | 2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $33.67 | 2022 | |
| Genentech USA, INC. | $31.38 | 2019-2025 | Actemra |
| Sobi, INC | $30.94 | 2019-2022 | |
| Radius Health, INC. | $22.65 | 2025 | Tymlos |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
| Sebela Pharmaceuticals INC. | $19.69 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.94 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.79 | 2022 | |
| Invivyd INC | $18.48 | 2025 | Pemgarda |
| Sanofi-Aventis U.S. LLC | $17.21 | 2019 | |
| Oxford Immunotec USA INC | $14.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Adhikari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.